BREO ELLIPTA

Peak

fluticasone furoate and vilanterol trifenatate

GSK

NDAINHALATIONPOWDER

Approved

May 2013

Lifecycle

Peak

Competitive Pressure

0/100

Clinical Trials

Data completeness

5/8 — Partial

Drug data last refreshed Yesterday · AI intelligence enriched 3w ago

AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data

BREO ELLIPTA is a combination inhaled powder containing fluticasone furoate (inhaled corticosteroid) and vilanterol (long-acting beta-2 agonist) approved by FDA in May 2013. It is indicated for maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD) in patients requiring regular controller therapy. The dual mechanism provides anti-inflammatory and bronchodilator effects through once-daily dosing via the proprietary ELLIPTA dry powder inhaler device.

$1.4BPart D

4.9 years to LOE

Mechanism of Action

Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (1)

NCT07223294Phase 3Not Yet Recruiting

Study to Evaluate the Therapeutic Equivalence and Safety of Fluticasone Furoate and Vilanterol Inhalation Powder 100 mcg/25 mcg and BREO ELLIPTA 100 mcg/25 mcg in Participants With Asthma

Started Apr 2026

1,430 enrolled

Respiratory

Why This Matters for Your Career

Worked on BREO ELLIPTA at GSK? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Career Relevance

BREO ELLIPTA as a peak-stage respiratory franchise supports career opportunities for brand managers, field sales representatives, medical science liaisons, and respiratory specialists focused on COPD and asthma management. Success in this role requires deep knowledge of pulmonary physiology, inhalation device technology, respiratory guidelines, and payer/formulary dynamics in the chronic disease space. Currently, zero job positions are linked to this product in the dataset, though the established market presence typically sustains ongoing commercial operations.